Factors affecting the pharmacokinetics of nifedipine.
The plasma pharmacokinetics of nifedipine and the formation of its metabolites have been studied in volunteers under conditions which would affect the activity of the cytochrome P-450 system. The pharmacokinetics of a 10-mg capsule of nifedipine were not significantly different between smokers and non-smokers of similar age. After pretreatment with cimetidine, which inhibits the activity of cytochrome P-450, the peak plasma concentration and area under the plasma-time concentration curve for nifedipine were increased by a mean 84%. In contrast, pre-treatment with ranitidine which has little effect on cytochrome P-450, did not significantly alter nifedipine pharmacokinetics. Smoking does not contribute significantly to the variability in nifedipine pharmacokinetics. However, the interaction between nifedipine and cimetidine, but not ranitidine, may be of clinical importance.
D000328:Adult; D002927:Cimetidine / Q000494:pharmacology; D003577:Cytochrome P-450 Enzyme System / Q000502:physiology; D004347:Drug Interactions; D006207:Half-Life; D006801:Humans; D007700:Kinetics; D008297:Male; D009543:Nifedipine / Q000378:metabolism*; D011899:Ranitidine / Q000494:pharmacology; D012907:Smoking
D002927:Cimetidine; D011899:Ranitidine; D003577:Cytochrome P-450 Enzyme System; D009543:Nifedipine